The application of QCT in the prognostic assessment of mCRC undergoing first-line treatment based on bevacizumab

作者：Xudong Liu, Shusheng Wu, Wenxi Dang, Hao Shen, Mingjie Sun, Yaolin Chen, Zhihua Zhang, Mengge Li, Zhirun Cai, Haoyu Wang, Fei Gao, Yifu He · 发表于：Future Oncology · 年份：2024 · DOI：10.1080/14796694.2024.2430160 · 被引用次数：1 · 研究领域：Colorectal Cancer Treatments and Studies、Nutrition and Health in Aging、Colorectal Cancer Surgical Treatments

BACKGROUND: Bevacizumab induces muscle atrophy by changing the gene expression level of muscle tissue. Quantitative computed tomography (QCT) enables precise measurement of various body compositions, including muscle area. MATERIALS & METHODS: A total of 102 patients with metastatic colorectal cancer (mCRC) undergoing first-line chemotherapy based on bevacizumab were enrolled at thirst Affiliated Hospital of the University of Science and Technology of China. Their body compositions were measured respectively 1 month before and 1 month after the treatment. RESULTS: Treatment-related decline in skeletal muscle index and visceral fat infiltration significantly affect patient prognosis. CONCLUSION: A predictive model constructed by integrating changes in body composition with patient clinical characteristics effectively predicts the 9-month progression-free survival (PFS) of patients with mCRC.